Related Experiment Video
Updated: Nov 9, 2025
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
7.4K
Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension
Mazen Al-Qadi1, Barbara LeVarge1, H James Ford1
1Division of Pulmonary and Critical Care Medicine, Pulmonary Hypertension Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Frontiers in Medicine
|April 12, 2021
Summary
Pulmonary hypertension (PH) in Group 5, associated with conditions like sarcoidosis and sickle cell disease, presents management challenges. Further research is needed to understand its epidemiology, pathogenesis, and treatment.
Area of Science:
- Cardiology
- Pulmonology
- Internal Medicine
Background:
- Pulmonary hypertension (PH) is classified into 5 groups based on associated conditions, pathophysiology, and clinical features.
- Group 5 PH encompasses conditions with less understood characteristics, posing management challenges.
Purpose of the Study:
- To review the current state of knowledge on Group 5 PH, including epidemiology, pathogenesis, and management.
- To identify research gaps and future directions for understanding Group 5 PH.
Main Methods:
- Literature review of the 6th World Symposium on PH classification.
- In-depth analysis of scientific literature on Group 5 PH entities.
Main Results:
- Group 5 PH includes conditions like sarcoidosis, sickle cell disease, myeloproliferative disorders, and chronic kidney disease.
- The nature of PH in these conditions is often unclear or multifactorial.
- Clinical management of Group 5 PH is challenging.
Conclusions:
- Group 5 PH requires further investigation to improve patient outcomes.
- Enhanced understanding of epidemiology and pathogenesis is crucial for developing targeted therapies.
- Future research should focus on clarifying the clinical course and optimizing management strategies for Group 5 PH.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
393
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
393
01:20COPD: Pathogenesis and Clinical Features
1.5K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.5K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.6K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
319
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
319
01:29Pulmonary Embolism I: Introduction
231
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
231
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.2K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.2K